Treatment of adolescent psychoses with olanzapine. A preliminary report

Nordic Journal of Psychiatry

Volumn 53, Issue 6, 1999, Pages 435-438

  Maagensen, Michael ^a,b   Aarkrog, Tove ^c  

^a Holbæk Centralsygehus ^*  (Denmark)

^b HOLBÆK HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Adolescents; Olanzapine; Psychosis

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; MOTOR DYSFUNCTION; PSYCHOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; WEIGHT GAIN;

EID: 0033507479     PISSN: 08039488     EISSN: None     Source Type: Journal    
DOI: 10.1080/080394899427674     Document Type: Article

References (6)

1. Angst J. European long-term follow up studies of schizophrenia. Schizophren Bull 1988;14:501-13.
2. Aarkrog T. Psychotic adolescents 20-25 years later. Nord J Psychiatry 1999;53 Suppl 42:1-37.
3. McGlashan T. Early detection and intervention in schizophrenia. Research. Schizophren Bull 1996;22:327-46.
4. Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53:281-98.
5. Kumran S, Jacobsen L, Lenane M, Karp B, Frazier J, Scmith A, et al. Childhood-onset schizophrenia: An open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998;37:377-85.
6. Shaffer D, Madelyn SG, Brasic J, Ambrosini P, Fiescher P, Bird H, et al. A Children's Global Assessment Scale (CGAS) for children (4-16 years of age). Arch Gen Psychiatry 1983;40:1228-31.